Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian W Flinn

Showing results (11-20 of 179) with videos related to

Pageof 18
Sort By:
Current Treatment Options in Oncology|March 14, 2017
Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?Michael T Tees, Ian W Flinn
Blood Reviews|November 14, 2006
Management of symptomatic, untreated chronic lymphocytic leukemiaYvette L Kasamon, Ian W Flinn
Current Oncology Reports|August 7, 2012
B-cell receptor pathobiology and targeting in NHLInes M Macias-Perez, Ian W Flinn
Current Hematologic Malignancy Reports|November 2, 2012
GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemiaInes M Macias-Perez, Ian W Flinn
Hematology. American Society of Hematology. Education Program|November 25, 2004
Chronic lymphocytic leukemiaJohn C Byrd, Stephan Stilgenbauer, Ian W Flinn
Current Treatment Options in Oncology|August 29, 2003
MALT LymphomasSami N Malek, Amy J Hatfield, Ian W Flinn
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2006
Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphomaIvan Aksentijevich, Richard J Jones, Richard F Ambinder, et al.
The Oncologist|May 11, 2019
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP ChemotherapyIan W Flinn, Jack Erter, Davey B Daniel, et al.
Current Stem Cell Research & Therapy|January 29, 2008
Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetanArturo Molina, Amrita Krishnan, Henry Fung, et al.
Blood|October 18, 2003
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemiaSherif S Farag, Ian W Flinn, Rama Modali, et al.
Pageof 18

Showing results (11-20 of 179) with videos related to

Sort By:
Pageof 18
Current Treatment Options in Oncology|March 14, 2017
Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?Michael T Tees, Ian W Flinn
Blood Reviews|November 14, 2006
Management of symptomatic, untreated chronic lymphocytic leukemiaYvette L Kasamon, Ian W Flinn
Current Oncology Reports|August 7, 2012
B-cell receptor pathobiology and targeting in NHLInes M Macias-Perez, Ian W Flinn
Current Hematologic Malignancy Reports|November 2, 2012
GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemiaInes M Macias-Perez, Ian W Flinn
Hematology. American Society of Hematology. Education Program|November 25, 2004
Chronic lymphocytic leukemiaJohn C Byrd, Stephan Stilgenbauer, Ian W Flinn
Current Treatment Options in Oncology|August 29, 2003
MALT LymphomasSami N Malek, Amy J Hatfield, Ian W Flinn
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2006
Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphomaIvan Aksentijevich, Richard J Jones, Richard F Ambinder, et al.
The Oncologist|May 11, 2019
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP ChemotherapyIan W Flinn, Jack Erter, Davey B Daniel, et al.
Current Stem Cell Research & Therapy|January 29, 2008
Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetanArturo Molina, Amrita Krishnan, Henry Fung, et al.
Blood|October 18, 2003
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemiaSherif S Farag, Ian W Flinn, Rama Modali, et al.
Pageof 18